Navigation Links
New drug shows promise against multiple sclerosis
Date:11/1/2011

An experimental drug called Ocrelizumab has shown promise in a Phase 2 clinical trial involving 220 people with multiple sclerosis (MS), an often debilitating, chronic autoimmune disease that affects an increasing number of people in North America. It usually strikes young adults and is more common in women than in men.

The study, carried out by researchers at the University of California, San Francisco (UCSF) Medical Center, and involving hospitals in the United States, Canada, and Europe, is described this week in the British medical journal Lancet.

The study involved patients with relapsing-remitting MS, a form of the disease marked by the accumulation of lesions in the brain and spinal cord and periodic "attacks" of neurological impairment.

The 220 patients were randomly enrolled into four groups two that received injections of the monoclonal antibody Ocrelizumab at two different doses, one that received the standard multiple sclerosis drug interferon-beta, and one "control" group that was given a placebo.

The doctors gauged the effectiveness of each treatment by performing monthly magnetic resonance imaging (MRI) brain scans of the patients and counting the number of visible marks that indicate inflamed lesions, a hallmark of the disease. They also compared the severity and frequency of neurological "attacks" that cause loss of vision, incoordination, weakness and numbness, among other symptoms.

The results of this trial showed that patients who received the drug generally fared well and showed fewer signs of the disease than patients who receive a placebo or the standard Interferon treatment. Overall, the trial found that Ocrelizumab led to a 89 percent reduction in the formation of brain lesions, and it also reduced the number of new multiple sclerosis attacks over 24 weeks. During this relatively short-term study, interferon performed no better than placebo on these outcomes.

"It really is
'/>"/>

Contact: Jason Socrates Bardi
jason.bardi@ucsf.edu
415-502-4608
University of California - San Francisco
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Preterm birth rate shows three year improvement in most states
2. Study shows no increased risk of breast cancer for non-carriers in families with BRCA gene mutation
3. Novel approach to treat proliferative vitreoretinopathy shows promise
4. New therapy shows promise for treating cardiovascular disease
5. More Evidence Shows Newer Forms of Pill Raise Clot Risk, FDA Says
6. New oncolytic virus shows improved effectiveness in preclinical testing
7. Clinical trial shows first evidence that anal cancer is preventable
8. Through-the-nipple breast cancer therapy shows promise in early tests
9. Compound found in common wart treatment shows promise as leukemia therapy
10. Study shows why underrepresented men should be included in binge eating research
11. HIV Medication Patch Shows Promise in Early Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2015)... Author Vincent N. Cefalu, Sr., MD. has always believed that ... of them aren’t aware of many products that are detrimental ... realize the dangers of physical inactivity and the many dangerous ... exist. There is also the fact that smokers ... In “ A Doctor’s Prescription for Longevity and Survival ” ...
(Date:5/25/2015)... The National Association of Professional ... inductee into its VIP Professional Woman of the Year ... leadership in dentistry. NAPW is the nation's leading networking ... members and over 200 operating local chapters. , ... of professional women,” said NAPW President Star Jones. “Her ...
(Date:5/25/2015)... 2015 The National Association of ... as a 2015-2016 inductee into its VIP Woman ... prestigious distinction for leadership in biomedical engineering. NAPW is ... boasting more than 700,000 members and over 200 operating ... this exceptional group of professional women," said NAPW President ...
(Date:5/25/2015)... York, New York (PRWEB) May 25, 2015 ... distributor of patented products, launches the Big Little Party ... to customize the perfect table that will suit their ... a whopping revenue of $646 billion this past year. ... a year industry" says Scott J. Cooper, CEO and ...
(Date:5/25/2015)... 24Hr HomeCare is proud to announce that David Allerby, ... Ryan Iwamoto, Co-Founder & CMO, are Finalists for the ... in Greater Los Angeles. The award is presented by ... performance, and a personal commitment to their communities. , ... success of our organization,” said Co-Founder & CEO, David ...
Breaking Medicine News(10 mins):Health News:New Book Reveals ‘A Doctor’s Prescription for Longevity and Survival’ 2Health News:New Book Reveals ‘A Doctor’s Prescription for Longevity and Survival’ 3Health News:National Association of Professional Women Inducts Dr. Laquinas Hooked, D.D.S. of General Dentist, Into its VIP Professional Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Lisa Ferrara, Ph.D., CEO of OrthoKinetic Technologies, Into its VIP Professional Woman of the Year Circle 2Health News:Party Time - Top Officials Get Excited About World Patent Marketing's New Party Invention For Entertainment 2Health News:Party Time - Top Officials Get Excited About World Patent Marketing's New Party Invention For Entertainment 3Health News:24Hr HomeCare Co-Founders Named Finalists for EY Entrepreneur of the Year 2015 Awards 2
... On Wednesday, September 14, Allan Coukell, a pharmacist and ... will testify before the Senate Health Education Labor and ... ensure the safety of the U.S. drug supply. ... now originate outside the U.S. Increasingly, Americans rely ...
... , FRIDAY, Sept. 9 (HealthDay News) -- One-third of ... metabolic disorder, a new study finds. This disorder ... naturally from many foods -- that has a foul, fishy ... disease that impairs the ability of an enzyme to metabolize ...
... human papillomavirus (HPV) vaccine Cervarix may be just as effective ... measures against cervical cancer, according to a new study published ... Cancer Institute . Across the globe, cervical cancer is ... 16 and 18 are a large contributor to the development ...
... Jenifer Goodwin HealthDay Reporter , THURSDAY, Sept. 8 ... or the death of a child in infancy have an ... study suggests. Researchers from the United Kingdom looked at ... stillborn child between 1971 and 2006 or whose child died ...
... each year with stage III or,locally advanced ... a viable,treatment option. Optimizing nonsurgical treatment strategies ... In an article published online,September 8, 2011 ... Institute, RTOG,researchers report that treating patients with ...
... HealthDay Reporter , THURSDAY, Sept. 8 (HealthDay News) -- ... rise, reaching 22.6 million, or 8.9 percent of the population, ... has largely been driven by more marijuana use, according to ... fact, in 2010 some 17.4 million Americans were using marijuana, ...
Cached Medicine News:Health News:Fewer than 3 doses of cervical cancer vaccine effective 2Health News:Losing Child in First Year Might Raise Early Death Risk for Parent 2Health News:Losing Child in First Year Might Raise Early Death Risk for Parent 3Health News:Concurrent chemo and radiation therepy improves long-term survival for inoperable stage III lung cancer 2Health News:More U.S. Adults Using Illegal Drugs: Report 2Health News:More U.S. Adults Using Illegal Drugs: Report 3
(Date:5/22/2015)... Fla. , May 22, 2015 ... Heart Institute recently traveled to Boston, ... procedure at the 2015 Heart Rhythm Society conference. ... together to focus on the ideas, people and ... Convergent is a hybrid, minimally invasive cardiac ...
(Date:5/22/2015)... -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage drug development ... announced that J.J. Finkelstein , chief executive officer ... at two upcoming investor conferences. Mr. ... Annual Microcap Conference on Thursday May 28, 2015 in ... am EDT.  A webcast will be available at the ...
(Date:5/22/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... of the results of the Company,s 72-patient, placebo-controlled ... drops) for the treatment of dry eye patients ... ) model.  The exploratory study was completed in ... disseminated by the Company in a press release, ...
Breaking Medicine Technology:St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 3RegeneRx to Present at 2 Investor Conferences 2RegeneRx to Present at 2 Investor Conferences 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: